Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 3/20 | 0.62 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | BLM | P54132 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | FDPS | P14324 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Phosphonate SCHEMBL7997370 | 1.00 | GABBR2 (0.62) | GABBR2GABBR1TSHRCYP1A2THPO | |
| Methyl Phosphonate SCHEMBL8007050 | 1.00 | GABBR2 (0.62) | GABBR2GABBR1TSHRCYP1A2THPO | |
| Methyl Phosphonate SCHEMBL7997691 | 1.00 | GABBR2 (0.62) | GABBR2GABBR1TSHRCYP1A2THPO | |
| Methyl Phosphonate SCHEMBL10823223 | 0.97 | GABBR2 (0.59) | GABBR2GABBR1TSHRCYP1A2THPO | |
| Methyl Phosphonate SCHEMBL7997367 | 0.90 | GABBR2 (0.65) | GABBR2GABBR1TSHRCYP1A2THPO | |
| Octadecylamine SCHEMBL28212235 | 0.89 | DNM1 (0.65) | GABBR2GABBR1TSHRCYP1A2THPO | |
| Methyl Phosphonate SCHEMBL8008672 | 0.89 | DNM1 (0.65) | GABBR2GABBR1TSHRCYP1A2THPO | |
| Phosphoric Acid SCHEMBL5382781 | 0.87 | LMNA (0.58) | GABBR2GABBR1TSHRCYP1A2THPO | |
| Phosphoric Acid SCHEMBL5177945 | 0.87 | LMNA (0.58) | GABBR2GABBR1TSHRCYP1A2THPO | |
| Phosphoric Acid SCHEMBL31656949 | 0.87 | LMNA (0.58) | GABBR2GABBR1TSHRCYP1A2THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795378-B2 | Iron control composition, make, and use in carbonate stimulation | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2023-10-24 | — | — | US | claimed |
| EP-1969025-B1 | CLEAR AND THICKENING AQUEOUS COMPOSITIONS, THE USE THEREOF IN ACIDIC AQUEOUS FORMULATIONS, AND THE RESULTING FORMULATIONS | COATEX SAS (FR) | 2018-02-21 | — | — | EP | claimed |
| US-20100152375-A1 | Thickening and Clear Aqueous Compounds, Their Use in Acid Aqueous Formulations, The Formulations Obtained | COATEX S.A.S. (FR) | 2010-06-17 | — | — | US | claimed |
| US-6265355-B1 | CHELATING AGENT SELECTED FROM THE GROUP CONSISTING OF PHOSPHONIC ACIDS CONTAINING UP TO 8 PHOSPHONATE GROUPS AND DERIVATIVES AND AN AMINO CARBOXYLIC ACID CONTAINING FROM 1 TO 5 CARBOXYL GROUPS | ATLANTIC RICHFIELD COMPANY | 2001-07-24 | — | — | US | claimed |
| EP-4326229-A1 | A COMPOSITION FOR USE IN THE TREATMENT OF OCULAR AFFECTIONS, SUCH AS DRY EYE DISEASE, ESPECIALLY AFTER EYE SURGERY | FARMIGEA S.P.A. (IT) | 2024-02-28 | — | — | EP | disclosed |
| EP-3823581-A1 | COMPOSITION COMPRISING GLYCYRRHIN AND COSMETIC AND PHARMACEUTICAL USES THEREOF | ATG 20 S.r.l. (IT) | 2021-05-26 | — | — | EP | disclosed |
| US-20210121497-A1 | COMPOSITION COMPRISING GLYCYRRHIN AND COSMETIC AND PHARMACEUTICAL USES THEREOF | ATG 20 S.R.L. (IT) | 2021-04-29 | — | — | US | disclosed |
| WO-2020016732-A1 | COMPOSITION COMPRISING GLYCYRRHIN AND COSMETIC AND PHARMACEUTICAL USES THEREOF | FARMIGEA S.P.A. (IT) | 2020-01-23 | — | — | WO | disclosed |
| US-20100152375-A1 | Thickening and Clear Aqueous Compounds, Their Use in Acid Aqueous Formulations, The Formulations Obtained | COATEX S.A.S. (FR) | 2010-06-17 | — | — | US | disclosed |
| EP-0460797-B1 | Methods of controlling scale formation in aqueous systems | BETZ EUROP INC (US) | 1995-06-21 | — | — | EP | disclosed |
| US-5409062-A | Using a polyepoxysuccinic acid | BETZ LABORATORIES, INC. (US) | 1995-04-25 | — | — | US | disclosed |
| US-5147555-A | Adding a substoichiometric amount of polyepoxysuccinic acid derivatives ot control calcium carbonate deposits | BETZ LABORATORIES, INC. (US) | 1992-09-15 | — | — | US | disclosed |
| US-H325-H | Electroless deposition of transition metals | RICHARDSON CHEMICAL COMPANY | 1987-09-01 | — | — | US | disclosed |
| EP-0210043-A2 | Contrast agent for NMR scanning | GUERBET S.A. (FR) | 1987-01-28 | — | — | EP | disclosed |
| EP-0073583-B1 | ELECTROLESS NICKEL-BORON PLATING | RICHARDSON CHEMICAL COMPANY (US) | 1986-03-12 | — | — | EP | disclosed |
| US-4503131-A | NICKEL-BORON OR NICKEL-PHOSPHORUS BARRIER LAYER | RICHARDSON CHEMICAL COMPANY (US) | 1985-03-05 | — | — | US | disclosed |
| US-4407869-A | Controlling boron content of electroless nickel-boron deposits | RICHARDSON CHEMICAL COMPANY (US) | 1983-10-04 | — | — | US | disclosed |
| EP-0084937-A1 | Electrical contact materials | RICHARDSON CHEMICAL COMPANY (US) | 1983-08-03 | — | — | EP | disclosed |
| EP-0073583-A1 | Electroless nickel-boron plating | RICHARDSON CHEMICAL COMPANY (US) | 1983-03-09 | — | — | EP | disclosed |
| US-4101441-A | AN AZOLE COMPOUND, ORGANOPHOSPHONIC ACID, A PHOSPHATE | CHEMED CORPORATION (US) | 1978-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121497-A1 | COMPOSITION COMPRISING GLYCYRRHIN AND COSMETIC AND PHARMACEUTICAL USES THEREOF | CD44, GYPA, GLA | GABBR2 828/4885GABBR1 637/4885TSHR 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.